Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, has successfully completed Phase 2 development in the U.S. and EU and Japan.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Appoints Kumi Sato to its Board of Directors

Addition of Japanese industry leader will help support Poxel’s corporate strategy for Imeglimin in Japan LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext –…

Read this Press Release: Poxel Appoints Kumi Sato to its Board of Directors

Poxel Announces Second Quarter 2017 Financial Update

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including…

Read this Press Release: Poxel Announces Second Quarter 2017 Financial Update

Poxel Presents New Preclinical Imeglimin Data on Improvement in Diastolic Function at the American Diabetes Association Meeting

Data from a model of metabolic syndrome suggest protective effects of Imeglimin on diabetic cardiomyopathy LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical…

Read this Press Release: Poxel Presents New Preclinical Imeglimin Data on Improvement in Diastolic Function at the American Diabetes Association Meeting
Click here to show the previous slide Click here to show the next slide